Last €43.30 EUR
Change Today -0.08 / -0.18%
Volume 12.9K
DBV On Other Exchanges
Symbol
Exchange
EN Paris
OTC US
NASDAQ GS
Frankfurt
Frankfurt
As of 8:00 AM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

dbv technologies sa (DBV) Snapshot

Open
€43.45
Previous Close
€43.38
Day High
€43.45
Day Low
€43.05
52 Week High
12/22/14 - €44.88
52 Week Low
01/3/14 - €10.78
Market Cap
828.2M
Average Volume 10 Days
31.7K
EPS TTM
€-1.42
Shares Outstanding
19.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DBV TECHNOLOGIES SA (DBV)

Related News

No related news articles were found.

dbv technologies sa (DBV) Related Businessweek News

No Related Businessweek News Found

dbv technologies sa (DBV) Details

DBV Technologies S.A. is engaged in the research, development, and marketing of products for the diagnosis and treatment of allergies, primarily food allergies in young children. The company provides Diallertest, a non-invasive patch allergy diagnostic for infants, children, or adults for the diagnosis of allergy in cow milk, wheat, and soybean. Its products include Viaskin Peanut, an immunotherapy product for the treatment of patients with peanut allergies; Viaskin Milk, for the treatment of CMPA and eosinophilic esophagitis, as well as food polyallergies; and Viaskin House Dust Mite, a mite desensitization product for the treatment of mite allergy. The company was founded in 2002 and is based in Bagneux, France.

48 Employees
Last Reported Date: 10/22/14
Founded in 2002

dbv technologies sa (DBV) Top Compensated Officers

Co-Founder, Chairman and Chief Executive Offi...
Total Annual Compensation: €280.0K
Compensation as of Fiscal Year 2013.

dbv technologies sa (DBV) Key Developments

DBV Technologies S.A. Presents at 7th Annual 2014 Deutsche Bank BioFEST, Dec-01-2014

DBV Technologies S.A. Presents at 7th Annual 2014 Deutsche Bank BioFEST, Dec-01-2014 . Venue: Four Seasons Hotel Boston, 200 Boylston Street, Boston, MA 02116, United States. Speakers: David Schilansky, Chief Financial Officer.

DBV Technologies Initiates Phase I/II Clinical Trial with Viaskin Milk for the Treatment of Children with Cow's Milk Allergy

DBV Technologies announced that it has begun enrolling cow's milk-allergic subjects in a Phase I/II clinical study to evaluate the safety and efficacy of Viaskin(R) Milk, an epicutanous patch for the treatment of children with IgE-mediated cow's milk allergy (CMA). The Viaskin MILk Efficacy and Safety Phase I/II study, or MILES study, is a multi-center, double-blind, placebo-controlled, randomized study designed to evaluate the safety and efficacy of Viaskin(R) Milk used to treat subjects on a daily basis by Epicutaneous Immunotherapy (EPIT(R)). The MILES study is composed of 2 parts. Part A, or Phase I, will evaluate the safety of three escalating doses of Viaskin(R) Milk (150 microgram, 300 microgram and 500 microgram cow's milk protein) versus placebo over three weeks. Part B, or Phase II, will evaluate the efficacy and safety of up to 12 months of EPIT with two selected doses of Viaskin(R) Milk from Part A. The primary efficacy endpoint is the percentage of treatment responders after 12 months of EPIT. Responders are subjects who meet one of the following criteria: a higher or equal to a 10-fold increase in the cumulative reactive dose (CRD) of cow's milk proteins at the Month 12 food challenge as compared to the baseline value and reaching at least 144 mg of cow's milk proteins (approximately 4.5 mL of milk); or a CRD of cow's milk proteins higher or equal to 1,444 mg (approximately 45 mL of milk) at the Month 12 food challenge. Bpifrance will be providing EUR 3 million in the form of an interest free loan (PTZI: Prêt à Taux Zero pour l'innovation) to DBV for the clinical development of Viaskin(R) Milk. This funding demonstrates Bpifrance's continued support for DBVs development programs. The interest-free loan provided by Bpifrance has a first date of payment as of June 30, 2017. After this initial payment, 19 linear quarterly payments will follow until March 31, 2022.

DBV Technologies S.A.(NasdaqGS:DBVT) added to NASDAQ Composite Index

DBV Technologies S.A. will be added to the NASDAQ Composite Index.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DBV:FP €43.30 EUR -0.08

DBV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ALK-Abello A/S kr654.00 DKK -6.00
Allergy Therapeutics PLC 24.50 GBp 0.00
Merck & Co Inc $57.78 USD +0.32
Sanofi €74.99 EUR -0.65
Stallergenes SA €48.99 EUR +0.31
View Industry Companies
 

Industry Analysis

DBV

Industry Average

Valuation DBV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 114.0x
Price/Book 18.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 137.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DBV TECHNOLOGIES SA, please visit www.dbv-technologies.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.